Collagen crosslinking (CXL) for keratoconus is known to decrease, halt, or even partially reverse progression of keratoconus. We report on a case where a substantial effect on scleral shape was also demonstrated. This keratoconus patient, who was successfully wearing a scleral lens, underwent collagen crosslinking OS. Three-months post crosslinking, the patient was unable to wear his previous scleral lens due to lens discomfort. Elevation mapping pre and post crosslinking, with a new corneal-scleral topography system, showed a decrease in size and change in shape of the cone, as well as a substantial change in the scleral elevation pattern at a 16-mm chord diameter. The change in the scleral elevation pattern was best observed on scleral shape plots which graph the sagittal height (SAG) value on the Y-axis vs. meridian on the X-axis. The pre-crosslinking plot resembled a standard toric curve although the depression inferiorly at 327° was deeper than that superiorly by >250µ. The post-crosslinking plot changed substantially with the steep axis superiorly being markedly attenuated: the SAG superiorly (106°) decreased post-crosslinking by >350µ. Attempts to virtually fit the eye surface post-crosslinking with a standard posterior toric haptic demonstrated a good fit superiorly and a poor fit inferiorly. The post-crosslinking scleral toricity plot was used to obtain quantitative information to manufacture a custom design conforming to this specific eye. The resulting lens was comfortable, well centred and resulted in a BCVA of 20/30.
keratoconus progressed in OS until in November 2016, the BCVA was 20/60 with the Hydrokone soft lens. The patient was measured with the sMap3D Cornealscleral topographer (Precision Ocular Metrology, Los Angeles, CA) for a scleral lens fitting, which predicted the need for a 2D toric peripheral haptic (the steps in how diopters of toricity were calculated have been reported in a previous publication.
5 ) The left eye was refit with the Europa Scleral lens (Visionary Optics, Front Royal, VA) using the lens parameters predicted by the sMap3D, which demonstrated a good, comfortable fit with a BCVA of 20/25. Significant steepening was noted from topography taken Oct 2016 compared to topography of Oct 2014 which correlated with loss of visual acuity. Crosslinking was recommended secondary to progression. Because of the history of keratoconus progression, the left eye underwent a CXL procedure in January 2017. By April 2017, the patient had restarted wear of the scleral lens but reported discomfort, redness, and difficulty removing the lens; the sMap3D examination was repeated. Figure 1 shows the pre and post crosslinking composite corneal and scleral elevation maps. The close-up inferior insets demonstrate a shrinking of the cone with CXL.
A change in the scleral elevation pattern is best observed on scleral shape plots 6 which are derived from the sagittal height (SAG) data on the corneal and scleral elevation maps; sagittal height at any point or any chord diameter from the corneal center can be directly calculated from the measured corneal and scleral elevation topography. Figure 2A demonstrates a scleral elevation map taken with the sMap3D of a case with 6.5 diopters of scleral toricity at a diameter of 16 mm around the center of the cornea. The steep axis is an area of depression (blue colour) on the surface. Figure 2B compares the scleral elevation map which is a visual qualitative assessment of scleral shape to the circumferential scleral shape plot which is a quantitative assessment. This graph plots the axis in degrees on the X-axis and the SAG value of the eye on the Y-axis (larger values as one goes down the scale) circumferentially at a radius of 8 mm (diameter of 16 mm) from the corneal center. Measuring circumferentially, in a case with regular toricity, an area of depression alternates with an area of elevation every 90°. This describes a toric (Sin 2 ) curve with a periodicity of 180°. In this particular case, the steep axes superiorly and inferiorly are represented by the low areas on the toricity plot and the flat axes are represented by the high areas. Note that each scale point on the Y-Axis is 0.2 mm (200µ) and from the highest to lowest point on the graph, the change in SAG is >1 mm (>1,000µ). Figure 3 demonstrates the scleral shape plots pre (A) and post (B) CXL graphed on the same scale. The post-CXL graph appeared to have at least 100µ less SAG in all meridians; the SAG superiorly (105.5°) decreased post-CXL by >350µ. The pre-crosslinking plot resembled more a standard toric peripheral curve (largely conforming to a Sin 2 curve with approximately 180° periodicity 6 ) although the depression inferiorly at 330° was deeper than that superiorly by 250µ. The   FIG. 2 Comparison of the scleral elevation map (A) to the scleral shape plot (B) in a case with high and fairly regular scleral toricity. The long arrows point to the same area of the sclera at a 16 mm diameter from the corneal centre. post-crosslinking plot had changed substantially with the steep axis superior depression being markedly attenuated.
The difference between the steep axis of the sclera superiorly and inferiorly post CXL was obvious on the 3D image (Figure 4) .
Attempts to virtually fit the post-crosslinking eye surface with the Europa scleral lens with a standard posterior toric haptic using the sMap3D software demonstrated a good fit superior-nasally and a poor fit (edge lift) inferior-temporally. This is demonstrated in the colour-coded 3D lens elevation map ( Figure 5 ) and the simulated fluorescein map ( Figure 6 ).
The post-crosslinking scleral shape plot was used to obtain quantitative information (Figure 7 ) to manufacture a custom (multi-meridian) design conforming to this specific eye. The resulting lens ( Figure 8 ) was comfortable, well centred and resulted in a BCVA of 20/30.
DISCUSSION

Wollensak, Spoerl and Seiler
1 first reported on the use of the CXL procedure to halt or reduce the progression of keratoconus in patients. Their work has been confirmed in multiple studies including in a recent randomized, prospective, double masked, sham controlled clinical trial 2 . In animal work, a significant increase in corneal biomechanical stiffness after the procedure was noted. 3 More recent animal studies in rabbits have demonstrated a similar stiffening effect with CXL on sclera both in vitro 7, 8 and longer term, 9 although in vitro studies on human sclera have had mixed results with one study showing no effect and
FIG. 4
Three-dimensional sagittal eye image in the superior-inferior plane demonstrating increased steepness inferiorly.
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another study showing a stiffening effect. 8, 10 Selective areas of stiffening of the sclera based upon riboflavin accumulation and UV light exposure could explain scleral shape changes observed. Alternately, it is possible that the observed changes are due crosslinking effects on the conjunctiva or even transmitted stress or tightening from the cornea; there is insufficient information to rule out any of these mechanisms. Regardless of the mechanism, it is not surprising that CXL can change scleral shape, however, up until recently, the means to measure scleral shape was not readily available clinically.
The patient was 44 and typically most KC patients have plateaued in their 40s (the cornea crosslinks naturally with age). Without change these patients aren't really candidates for crosslinking. However, in this case, the patient progressed and the standard of care is to have those patients evaluated and treated accordingly.
Could these observed differences in pre to post CXL measurements be simply due to measurement variability? A number of factors mitigate against this possibility. Firstly, some sort of change undoubtedly occurred on the ocular surface to explain why a well-fitting scleral lens, fit using the sMap3D fitting algorithm, no longer fit on the eye post CXL 3 months later. Secondly, the post CXL surface data was used to modify the fit in a highly customized fashion and was highly successful. Thirdly, the changes observed pre and post CXL are outside the range of variability observed in sMap3D repeatability studies. The repeatability of measurements with the sMap3D instrument has been reported in 2 series of cases; 19 normal eyes 11 and 25 eyes scheduled for scleral lens fitting. 5 The mean difference in SAG between the 2 exams in the first series was 6µ with a standard deviation of 40µ. The SAG difference between exams was ±25µ in 39% of cases, ±50µ in 78% of cases, ±75µ in 94% of cases and all cases within ±100µ. In the second series, the mean difference in SAG between the 2 examinations was 14µ with a SD of 55 µ. Sixty-eight percent of cases had a difference of ≤50µ, and 95% of cases had a difference of ≤100µ. The change in SAG, pre to post CXL, was 126µ which was outside the range of mean ± 2 standard deviations in both series 
FIG. 7
Post-crosslinking scleral shape plot at a 16 mm diameter used to design a custom back surface scleral lens. These 4 data points and similar data from 14 mm and 15 mm diameter plots were programmed into the scleral lens manufacturing lathe software to produce this lens custom peripheral back surface.
FIG. 8
Post-crosslinking eye fit with a custom back surface scleral lens based upon scleral shape plots. The lens was well centred with a comfortable fit. making it highly unlikely that these findings are due to measurement variability. Differences in centration of the cornea between topography examinations can effect mapping measurements however the sMap3D ameliorates this issue. Integral to the mapping and stitching of the images in a single examination is the identification of the limbus; this is done automatically by the software but can be over-ridden by the user in complex cases. By using the limbal position as a fixed point in both pre and post CXL exams, it is highly unlikely that centration differences were a factor.
This patient, wearing a well-fitting scleral lens for 2 months, underwent a CXL procedure. Three months post CXL, the lens no long fit the eye. Because corneal-scleral topography was done pre and post CXL, the changes induced by the procedure could be documented. The sMap3D instrument was able to provide quantitative data sufficient to design a well-fitting custom back surface scleral lens. With the growing use of the CXL procedure, the scleral lens fitter should be aware of a possible change in the scleral shape and monitor these patients closely.
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